Grace Therapeutics, Inc. financial data

Symbol
GRCE, ACST on Nasdaq
Industry
Pharmaceutical Preparations
Location
103 Carnegie Center, Suite 300, Princeton, NJ
State of incorporation
DE
Fiscal year end
March 31
Former names
Acasti Pharma Inc. (to 10/25/2024)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1K % -11.3%
Debt-to-equity 17.6 % +0.63%
Return On Equity -19.2 % +64.8%
Return On Assets -16.3 % +64.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.1M shares +7.88%
Common Stock, Shares, Outstanding 9.4M shares +26.4%
Entity Public Float 17.6M USD
Common Stock, Value, Issued 258M USD +0.04%
Weighted Average Number of Shares Outstanding, Basic 11.5M shares +52.3%
Weighted Average Number of Shares Outstanding, Diluted 11.5M shares +52.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.81M USD +56.1%
Selling and Marketing Expense 252K USD -61.9%
General and Administrative Expense 7.04M USD -6.45%
Operating Income (Loss) -16.1M USD +67.1%
Nonoperating Income (Expense) 1.82M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -14.3M USD +71.5%
Income Tax Expense (Benefit) -2.67M USD +72.9%
Net Income (Loss) Attributable to Parent -11.6M USD +71.2%
Earnings Per Share, Basic -0.92 USD/shares +83%
Earnings Per Share, Diluted -0.92 USD/shares +83%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.2M USD -43.9%
Accounts Receivable, after Allowance for Credit Loss, Current 398K USD -52.4%
Assets, Current 16.1M USD -44.4%
Property, Plant and Equipment, Net 24K USD -76.9%
Operating Lease, Right-of-Use Asset 0 USD -100%
Intangible Assets, Net (Excluding Goodwill) 41.1M USD 0%
Goodwill 8.14M USD 0%
Assets 65.3M USD -16.4%
Employee-related Liabilities, Current 373K USD +81.1%
Accrued Liabilities, Current 814K USD -18.1%
Liabilities, Current 2.67M USD +91.4%
Deferred Income Tax Liabilities, Net 3.94M USD -40.4%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 9.22M USD -19.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -6.04M USD 0%
Retained Earnings (Accumulated Deficit) -217M USD -5.65%
Stockholders' Equity Attributable to Parent 56.1M USD -15.9%
Liabilities and Equity 65.3M USD -16.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.6M USD +42.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -15K USD
Common Stock, Shares, Issued 9.4M shares +26.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.61M USD +42.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.2M USD -43.9%
Deferred Tax Assets, Valuation Allowance 47.3M USD +1.33%
Deferred Tax Assets, Gross 51.6M USD +11.1%
Operating Lease, Liability 0 USD -100%
Depreciation 1K USD -85.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.43M USD -4.86%
Lessee, Operating Lease, Liability, to be Paid 24K USD
Property, Plant and Equipment, Gross 722K USD +1.26%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 105K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 24K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 108K USD
Deferred Tax Assets, Operating Loss Carryforwards 40.7M USD +5.26%
Lessee, Operating Lease, Liability, to be Paid, Year Four 112K USD
Additional Paid in Capital 18.3M USD +5.75%
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 326 USD -26.4%